Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Laurie S. Davis"'
Autor:
Amy M Becker, Kathryn H Dao, Bobby Kwanghoon Han, Roger Kornu, Shuchi Lakhanpal, Angela B Mobley, Quan-Zhen Li, Yun Lian, Tianfu Wu, Andreas M Reimold, Nancy J Olsen, David R Karp, Fatema Z Chowdhury, J David Farrar, Anne B Satterthwaite, Chandra Mohan, Peter E Lipsky, Edward K Wakeland, Laurie S Davis
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67003 (2013)
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterized by defective immune tolerance combined with immune cell hyperactivity resulting in the production of pathogenic autoantibodies. Previous gene expression studies
Externí odkaz:
https://doaj.org/article/fa7ba6fef3494bf898048d039e41f0e6
Autor:
Laurie S. Davis, Andreas M. Reimold
Publikováno v:
Rheumatology. 56:i100-i113
This review summarizes traditional and emerging therapies for SLE. Evidence suggests that the heterogeneity of SLE is a crucial aspect contributing to the failure of large clinical trials for new targeted therapies. A clearer understanding of the mec
Autor:
Laurie S. Davis, Andreas M. Reimold
Publikováno v:
Experimental and Therapeutic Medicine
Anti-nuclear antibodies (ANAs) may be induced in patients with rheumatoid arthritis (RA) receiving anti-tumor necrosis factor (TNF) therapy with TNF inhibitors (TNFi), etanercept, infliximab or adalimumab. In the present study, 11 patients who were T
Autor:
Teja Celhar, Anna-Marie Fairhurst, Anne B. Satterthwaite, Laurie S. Davis, Petra D. Cravens, Olga Zharkova
Publikováno v:
Rheumatology (Oxford, England)
SLE is a chronic autoimmune disease caused by perturbations of the immune system. The clinical presentation is heterogeneous, largely because of the multiple genetic and environmental factors that contribute to disease initiation and progression. Ove
Autor:
Peter E. Lipsky, Sarah E Heuer, Matthew Ryals, Amrie C. Grammer, Rob D Robl, Michelle D. Catalina, Laurie S. Davis, Bernard Lauwerys, Sushma Madamanchi
Publikováno v:
Lupus. 25:1150-1170
Lupus patients are in need of modern drugs to treat specific manifestations of their disease effectively and safely. In the past half century, only one new treatment has been approved by the US Food and Drug Administration (FDA) for systemic lupus er
Autor:
Laurie S. Davis, Xiangmei Kong, Ann M. Stowe, Wendy I. White, Yue Wang, Nancy L. Monson, Ronald Herbst, Ding Chen, Sara J. Ireland
Publikováno v:
The Journal of Immunology. 196:1541-1549
The contribution of autoantibody-producing plasma cells in multiple sclerosis (MS) remains unclear. Anti-CD20 B cell depletion effectively reduces disease activity in MS patients, but it has a minimal effect on circulating autoantibodies and oligoclo
Publikováno v:
Cytokine. 73:236-244
The cytokines IL-6 and IL-10 are produced by cells of the adaptive and innate arms of the immune system and they appear to play key roles in genetically diverse autoimmune diseases such as relapsing remitting multiple sclerosis (MS), rheumatoid arthr
Autor:
Laurie S. Davis
Publikováno v:
Arthritis & Rheumatology. 67:1147-1150
Autor:
Laurie S. Davis
Publikováno v:
Nature immunology
Cross-regulation of Toll-like receptor responses by cytokines is essential for effective host defense, avoidance of toxicity, and homeostasis, but the underlying mechanisms are not well understood. A comprehensive epigenomic approach in human macroph
Autor:
Laurie S. Davis
Publikováno v:
Science Immunology. 2
A transancestral SLE study examining the relationship between genetic load and disease risk.